Classification and scoring systems in myelodysplastic syndromes: A retrospective analysis of 311 patients

Leukemia Research

Volumn 30, Issue 8, 2006, Pages 971-977

  Navarro, I ^a   Ruiz, M A ^a   Cabello, A ^b   Collado, R ^b   Ferrer, R ^a   Hueso, J ^b   Martinez, J ^a   Miguel, A ^b   Orero, M T ^b   Perez P ^b   Nolasco, A ^c   Carbonell, F ^b  

^a HOSPITAL FRANCESC DE BORJA   (Spain)

^b HOSPITAL GENERAL UNIVERSITARIO DE VALENCIA   (Spain)

^c UNIVERSITY OF ALICANTE   (Spain)

Author keywords

FAB classification; Myelodysplastic syndromes; Prognosis; Prognostic scoring system; WHO classification

Indexed keywords

ADULT; AGED; ARTICLE; CHROMOSOME ANALYSIS; CONTROLLED STUDY; DISEASE CLASSIFICATION; ERYTHROID CELL; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; MYELODYSPLASTIC SYNDROME; PRIORITY JOURNAL; PROGNOSIS; REFRACTORY ANEMIA; REFRACTORY ANEMIA WITH RINGED SIDEROBLASTS; REFRACTORY CYTOPENIA WITH MULTILINEAGE DYSPLASIA; RISK ASSESSMENT; SURVIVAL TIME; WORLD HEALTH ORGANIZATION;

ADULT; AGED; AGED, 80 AND OVER; ANEMIA, REFRACTORY; ANEMIA, SIDEROBLASTIC; CYTOGENETIC ANALYSIS; FEMALE; HUMANS; KARYOTYPING; MALE; MIDDLE AGED; MYELODYSPLASTIC SYNDROMES; PROGNOSIS; RETROSPECTIVE STUDIES; SEVERITY OF ILLNESS INDEX; SURVIVAL ANALYSIS; SURVIVAL RATE; TIME FACTORS; WORLD HEALTH ORGANIZATION;

EID: 33646813836     PISSN: 01452126     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.leukres.2005.11.015     Document Type: Article

References (39)

1. Bennett J.M., Catovsky D., Daniel M.T., Flaudin G., Galton D.A.G., Gralnick H.R., et al. Proposals for the classification of the myelodysplastic syndromes. Br J Haematol 51 (1982) 189-199
2. Mufti G.J., Stevens J.R., Oscien D.G., Hamblin T.J., and Machin M. Myelodysplastic syndromes: a scoring system with prognostic significance. Br J Haematol 59 (1985) 425
3. Bennett J.M., Catovsky D., Daniel M.T., Flaudin G., Galton D.A.G., Gralnick H.R., et al. The chronic myeloid leukemias guidelines for distinguishing chronic granulocytic atypical chronic myeloid and chronic myelomonocytic leukemia. Proposals by the French-American-British Cooperative Leukemia Group. Br J Haematol 87 (1994) 476
4. Michaux J.L., and Martiat P. Chronic myelomonocytic leukemia (CMML): a myelodysplastic or myeloproliferative syndrome. Leuk Lymphoma 9 (1993) 35
5. Groupe Francais de Cytogenetique Hématologique. Chronic myelomonocytic leukemia: single entity or heterogeneous disorder? A prospective multicenter study of 100 patients. Cancer Genet Cytogenet (1991) 55
6. Vallespi T., Torrabadella M., Julia A., Irriquible D., Jaen A., Acebedo G., et al. Myelodysplastic syndromes: a study of 101 cases according to de FAB classification. Br J Haematol 61 (1985) 83
7. Sanz G.F., Sanz M.A., Vallespi T., and Canizo M. Two regression models and a scoring system for predicting survival and planning treatment in myelodysplastic Syndromes: a multivariate analysis of prognostic factors in 370 patients. Blood 74 (1989) 395
8. Aul C., Gatterman N., Heyll A., and Germing V. Primary myelodysplastic syndromes: analysis of prognostic factors in 235 patients and proposals for an improved scoring system. Leukemia 6 (1992) 52
9. Matsuda A., Jinnai I., Yagasaki F., Kusumito S., Murohashi J., Bessho M., et al. New system for assessing the prognosis of refractory anemia patients. Leukemia 13 (1999) 1727
10. In: Jaffes E.S., Harris N.L., Stein H., and Vardiman J.W. (Eds). Pathology and genetics of tumours of hematopoietic and lymphoid tissues (2001), IARC Press, Lyon 61-73
11. Germing U., Gattermann N., Strupp C., Aivado M., and Aul C. Validation of the WHO proposals for a new classification of primary myelodysplastic syndromes: a retrospective analysis of 1600 patients. Leuk Res 24 (2000) 983
12. Greenberg P., Cox C., Lebeau M., Fenaux P., Morel P., Sanz G., et al. International scoring system for evaluating prognosis in myelodysplastic syndromes. Blood 98 6 (1997) 2079
13. Seymour J.F., and Estey E.H. The contribution of Auer rods to the classification and prognosis of myelodysplastic syndromes. Leuk Lymphoma 17 (1995) 79
14. Aul C., Gattermann N., Germing U., Runde V., Heyll A., and Scheider W. Risk assessment in primary myelodysplastic syndromes: validation of the Düsseldorf score. Leukemia 8 (1994) 1906
15. Nosslinguer T., Reisner R., Koller E., Gruner E., Tucher H., Nowotny H., et al. Myelodysplastic syndromes, from French-American-British to World Health Organization: comparison of classifications of 431 unselected patients from a single institution. Blood 98 (2001) 2935
16. Germing Gattermann N., and Minning H. Problems in the classification of CMML-dysplastic versus proliferative type. Leuk Res 22 10 (1998) 871
17. Howe R., Porwit-MacDonald A., Wanat R., Tehranchi R., and Hellstrom-Linderg E. The WHO classification of MDS does make a difference. Blood 103 9 (2004) 3265
18. Seabright M.R. A rapid banding technique for human chromosomes. Lancet 2 (1971) 971
19. Mitelman F, Karger S. Basel: an international system for human cytogenetic nomenclature (ISCN). Basel: S Karger; 1995.
20. Kaplan E., and Meier P. Nonparametric stimation from incomplete observations. J Am Stat Assoc 53 (1958) 457
21. Cox D.R. Regression models and life tables. JR Stat Soc 31 (1972) 187
22. Rosati S., Mick R., Xu F., Stonys E., LeBeau M.M., Larson R., et al. Refractory cytopenia with multilineage dysplasia: further characterization of an unclassifiable myelodysplastic syndrome. Leukemia 10 (1996) 20
23. Matsuda A., Jinnai I., Yagasaki F., Kusumoto S., Minamahisamato M., Honda S., et al. Refractory anemia with severe dysplasia: clinical significance of morphological features in refractory anemia. Leukemia 12 (1998) 482
24. Gattermann N., Aul C., and Schneider W. Two types of an acquired idiopathic sideroblastic anaemia (AISA). Br J Haematol 74 (1990) 45
25. Garand R., Gardais J., and Bizet M. Heterogeneity of acquired idiopathic sideroblastic anemia (AISA). Leuk Res 16 (1992) 463
26. Kuriyama K., Miyazaki Y., Arimura K., Nagai K., Nakamura H., Matsuo T., et al. Morphological comparison of dysplastic changes between de novo acute leukemia (AML) with trilineage myelodysplasia and AML developed from de novo myelodysplastics syndromes. Leuk Res 19 (1995) 121
27. Greenberg P., Anderson J., de Witte T., Estey E., Fenaux P., and Gupta P. Problematic WHO re-classification of myelodysplastics syndromes. Members of the international MDS study group. J Clin Oncol 18 (2000) 3447-3452
28. Estey E., Thall P., Beran M., Kantarjian H., Pierce S., and Keating M. Effect of diagnosis refractory anemia with excess blast, refractory anemia with excess blast in transformation, or acute myeloid leukemia (AML) on outcome of AML-type chemotherapy. Blood 90 (1997) 2969-2977
29. Steensma D.P., and Tefferi A. The myelodisplastic syndrome (S): a prospective and review highlighting current controversies. Leuk Res 27 (2003) 95-120
30. Balduini C.L., Guarnome R., Pecci A., Lentenara E., and Ascari E. Multilineage dysplasia without increased blast identifies a poor prognosis subset of myelodysplastic syndromes. Leukemia 12 (1998) 1655-1656
31. Germing V., Gattermann N., Aviado M., Hilderbrand B., and Aul C. Two types of acquired idiopathic syderoblastic anemia (AISA): a time-tested distribution. Br J Haematol 108 (2000) 724-728
32. Schanz J, Wulich J, Fonatsch C, Haase D. Cytogenetic findings confirm blast count threshold in MDS is at 10%. Blood 2000; 96:148.
33. Lorand-Metze I., Pinheiro M.P., Ribeiro E., Paula E.V., and Metze K. Factors influencing survival in myelodysplatic syndromes in a Brazilian population: comparison of FAB and WHO classifications. Leuk Res 28 (2004) 587-594
34. Lee J.H., Shi Y.R., Lee J.S., Kim W.K., Chi H.S., Park C.J., et al. Application of different prognostic scoring systems and comparison of the FAB and WHO classifications in Korean patients with myelodysplastic syndrome. Leukemia 17 (2003) 305-313
35. Gatterman N. From syderoblastic anemia to the role of mitochondrial DNA mutations in myelodysplastic syndromes. Leuk Res 24 (1999) 141-151
36. Cermak J., Belickova M., Krejcova H., Michalova K., Ziloucova S., Zemanova Z., et al. The presence of clonal cell subpopulation in peripheral blood and bone marrow of patients with refractory cytopenia with multilineage dysplasia but not in patients with refractory anemia may reflect a multistep pathogenesis of myelodisplasia. Leuk Res 29 (2005) 371-379
37. Aul C., Derming V., Gatterman N., and Minning H. Increasing incidence of myelodysplastic syndromes: real or fictitious. Leuk Res 22 (1998) 93-100
38. Cermak J., Vitek A., and Michalova K. Combined stratification of refractory anemia according to both WHO and IPSS criteria has a prognostic impact and improves identification of patient who may be benefit from stem cell transplantation. Leuk Res 28 (2004) 551-557
39. Malcovati L., Porta M.G., Pascutto C., Invernizzi R., Boni M., Travaglino E., et al. Prognostic factors and life expectancy in myelodysplastic syndromes classified according to WHO criteria: a basis for clinical decision making. J Clin Oncol 30 (2005) 7594-7603